Selection from HEOR Bibliography

IMS logo
Search criteria
Country: Slovakia
 
Patient and caregiver indirect costs after acute cardiovascular events in Europe.
Authors: Sidelnikov E1, Gerlier L2, Kutikova L1, Amarenco P3, Kotseva K4, Annemans L5
Affiliations: 1 Amgen (Europe) GmbH, Zug, Switzerland 2 IQVIA, Zaventem, Belgium 3 Paris-Diderot-Sorbonne University, Paris, France 4 National Heart & Lung Institute, Imperial College London, London, UK 5 Ghent University, Ghent, Belgium
Publications: 
ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain
Document Types: , Oral presentation
Countries: , Austria, Bulgaria, Croatia, Czech, Denmark, Finland, Germany, Greece, Italy, Norway, Romania, Slovakia, Slovenia
Abstract: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/84816?pdfid=58963
Condition Year Language Analysis type
, Cardiovascular disease, Health economics 2018 English , Burden of illness, Cost of illness
 
 
Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature.
Authors: Svedman FC1, Pillas D2, Taylor A2, Kaur M2, Linder R3, Hansson J1.
Affiliations: 1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden. 2Centre for Observational Research, Amgen Ltd, Uxbridge, UK. 3IMS Health Sweden, Stockholm, Sweden.
Publications: 
Clinical Epidemiology
Document Types: , Article
Countries: , Australia, Austria, Belgium, Bulgaria, Croatia, Czech, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK
Abstract: http://www-ncbi-nlm-nih-gov.proxy.kib.ki.se/pmc/articles/PMC4887072/
Condition Year Language Analysis type
, Oncology 2016 English , Literature Review
 
 
Survey on appropriateness of use of nimesulide in nine European countries
Authors: Franchi S1, Heiman F2, Visentin E2, Sacerdote P1.
Affiliations: 1Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy. 2Cegedim Strategic Data Medical Research Srl, Milan, Italy.
Publications: 
Drug, Healthcare and Patient Safety 2015:7 51-55
Document Types: , Article
Countries: , Bulgaria, Czech, Greece, Hungary, Italy, Poland, Portugal, Romania, Slovakia
Condition Year Language Analysis type
, Pain 2015 English , Survey research
 
 
Health economic evaluation of canagliflozin in the treatment of type 2 diabetes mellitus in Slovakia
Authors: Troelsgaard A1, Pitcher A2, Binder R3, Stetka R4, Ondrusova M5, Lovato E2, Hemels M1
Affiliations: Janssen A/S, Birkerød, Denmark, 2IMS Health, London, UK, 3Janssen, Bratislava, Slovak Republic, 4Pharm-In, Ltd, Bratislava, Slovak Republic, 5Pharm-In Ltd, Bratislava, Slovak Republic
Publications: 
ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands
Document Types: , Poster
Countries: , Slovakia
Condition Year Language Analysis type
, Diabetes 2014 English , Economic evaluation
 
 
Prevention of stroke in patients with Atrial Fibrillation: Cost-Utility Analysis of Rivaroxaban versus Warfarin in Slovakia
Authors: Psenkova M1, Lukac M2, Mackovicova S3, Stachova M2, Bielik J4, Pietsch GA5, Asukai Y6, Lloyd A6, Evers T7
Affiliations: 1Pharm-In, Bratislava, Slovak Republic, 2Bayer, Bratislava, Slovak Republic, 3Pharm-In, spol. s r.o., Bratislava, Slovak Republic, 4Trencin University, Trencin, Slovak Republic, 5Bayer Schering Pharma AG, Wupertal, GA, Germany, 6IMS Health, London, UK, 7Bayer Schering Pharma AG, Wuppertal, Germany
Publications: 
ISPOR 15th Annual European Congress, 3-7 November 2012, Berlin, Germany
Document Types: , Poster
Countries: , Slovakia
Abstract: http://www.ispor.org/congresses/Berlin1112/Posters2.aspx
Condition Year Language Analysis type
, Cardiovascular disease 2012 English , Cost utility
 
 
Cost-utility analysis of Rivaroxaban compared with Enoxaparin in prevention of venous thromboembolism after total hip replacement in Slovakia
Authors: Pereira R1, Diamantopoulos A2, Bielik J3, Lees M4, Tomek D5, Lukac M6
Affiliations: 1IMS Health, Barcelona, Spain, 2IMS Health HEOR, London, UK, 3University of A.Dubcek in Trencin, Bratislava, Slovak Republic, 4Bayer plc, Uxbridge, UK, 5Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic, 6Faculty of Public Health at Slovak Medical University, Bratislava, Slovak Republic
Publications: 
ISPOR 15th Annual International Meeting, May 15-19, 2010, Atlanta, GA, USA
Document Types: , Poster
Countries: , Slovakia
Abstract: http://www.ispor.org/meetings/atlanta0510/Posters3.aspx
Condition Year Language Analysis type
, Vascular disease 2010 English ,
 
 
Copyright 2019 IMS Health Incorporated. All rights reserved.